What is this study studying for pelvic metastasis?

This study is evaluating whether patients experience early functional improvement after receiving minimally-invasive placement of Illuminoss photodynamic nails for pelvic metastases. Researchers are also assessing pain relief, implant stability, and complication rates. The study is sponsored by M.D. Anderson Cancer Center to better understand this treatment approach for pelvic metastasis.

Who may be eligible for this pelvic metastasis clinical trial?

Adults aged 18 or older with a confirmed cancer diagnosis involving the area around the hip socket may be eligible. Participants must be able to undergo general anesthesia and willing to complete functional surveys. Pregnant women and those with certain allergies or uncontrolled illnesses are excluded. Please review eligibility criteria for more details.

Is there any cost to participate in this pelvic metastasis clinical trial?

Study-related care, including the photodynamic nail procedure and all trial visits, is provided at no cost. However, personal travel and other expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for these potential costs.

Actively Recruiting

Phase 1

Age: 18Years +

All Genders

ID06083896

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails A Multi-center Prospective Study of Functional Outcome

Led by M.D. Anderson Cancer Center · Updated on 2026-03-02

Participants Needed

Research Sites

104 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the early functional improvement in patients with peri-acetabular pelvic metastasis after minimally-invasive placement of Illuminoss photodynamic nails. This multi-center prospective study aims to assess functional outcomes at 3 months post-procedure and also looks at pain relief, radiographic stability, and complications related to the implant. The trial is sponsored by M.D. Anderson Cancer Center and is conducted as a Phase 1 interventional study. The study involves placing photodynamic nails through a stab incision at the entry site in patients with pelvic metastases. The procedure uses general anesthesia and is minimally invasive. Researchers will evaluate the patients functional outcomes at various time points, including 2 weeks, 6 weeks, 3 months, 6 months, and possibly later. The study also monitors for reoperation rates and complications associated with the implant. Participants will be asked to complete pre-operative and post-operative functional outcome surveys. Safety is closely monitored through tracking adverse events graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, up to one year after the procedure. The study requires participants to be able to understand and consent, and their blood counts will be checked to ensure eligibility. Overall participation involves regular assessments to observe functional improvements and implant stability.

CONDITIONS

Brief Title

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Patients must have a confirmed diagnosis of cancer from prior biopsy of the primary tumor or metastatic site, including carcinoma, myeloma, or lymphoma
Metastatic involvement must be visible near the hip socket on imaging
Age 18 years or older
Suitable candidate for general anesthesia
Able to understand and willing to sign informed consent
Willing to complete pre- and post-operative functional surveys
Absolute neutrophil count of at least 1,500/mcL
Platelet count of at least 50,000/mcL

You will not qualify if you...

Patients with uncontrolled illnesses that increase anesthesia risk, such as recent pneumonia or heart attack
Pregnant women due to risks from anesthesia and fluoroscopy
Patients with psychiatric or social issues limiting study compliance
History of allergic reactions to materials similar to dental resins or PET
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible

Research Team

Patrick Lin, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here